Cis-targeted immunotherapies that selectively activate specific immune cell types for cancer and autoimmune diseases.
Asher Bio develops cis-targeted immunotherapies designed to activate only the immune cell types needed for a therapeutic effect. Their approach uses two-molecule targeting on the same immune cell—an immunomodulatory receptor and a cell-specific target—to achieve selectivity and reduce toxicity compared to conventional immunotherapies. Their lead program, etakafusp alfa (formerly AB248), is a cis-targeted IL-2 that preferentially activates CD8+ effector T cells, currently in Phase 1a/1b clinical trials with promising anti-tumor activity and a tolerable safety profile. Asher Bio is a product of Asher Bio.